Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

van Meerten, T., Kersten, M. J., Iacoboni, G., Hess, G., Mutsaers, P., Martín García-Sancho, A., … Wang, M. (2024). Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi). Blood, 144(Supplement 1), 748–748. https://doi.org/10.1182/blood-2024-198021